Quarterly ResultAug 5, 2026, 04:24 PM
AbCellera Secures $112M Upfront from Jazz & Vertex Deals; Q2 Net Loss $55.4M
AI Summary
AbCellera reported a Q2 2026 net loss of $55.4 million, or $(0.18) per share, on revenue of $4.1 million, a significant decrease from Q2 2025. Despite the financial decline, the company announced two new collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, securing $112 million in total upfront payments. These partnerships leverage AbCellera's T-cell engager platform for oncology and autoimmune diseases, with potential for substantial future milestone payments and royalties. The company maintains over $675 million in total available liquidity.
Key Highlights
- Secured $84M upfront from Jazz Pharmaceuticals for T-cell engager collaboration.
- Received $28M upfront from Vertex Pharmaceuticals for multispecific TCE collaboration.
- Reported Q2 2026 revenue of $4.1 million, down from $17.1 million in Q2 2025.
- Net loss for Q2 2026 was $55.4 million, or $(0.18) per share.
- Ended Q2 2026 with over $675 million in total available liquidity.
- ABCL635 Phase 2 top-line data expected in August 2026.
- Appointed Dr. Victor Sandor and Dr. Lynn Seely as independent directors.
Price Impact
More from ABCL